# New Combination Inhaler (FlutiForm HFA MDI 100/10 µg and 250/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo in Patients With Moderate to Severe Asthma

> **NCT00393952** · PHASE3 · COMPLETED · sponsor: **SkyePharma AG** · enrollment: 557 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Fluticasone propionate/Formoterol fumarate 250/10
- **DRUG:** Placebo
- **DRUG:** Fluticasone propionate/Formoterol fumarate 100/10
- **DRUG:** Fluticasone propionate 250
- **DRUG:** Formoterol fumarate 10

## Key facts

- **NCT ID:** NCT00393952
- **Lead sponsor:** SkyePharma AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-06
- **Primary completion:** 2008-04
- **Final completion:** 2008-04
- **Target enrollment:** 557 (ACTUAL)
- **Last updated:** 2011-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00393952

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00393952, "New Combination Inhaler (FlutiForm HFA MDI 100/10 µg and 250/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo in Patients With Moderate to Severe Asthma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00393952. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*